Background and Aims: Eosinophilic bronchitis (EB) is a disease characterized by chronic cough and airway eosinophil infiltration, responsive to hormone therapy but without airway hyperreactivity (AHR). To date, there is no mouse model established with those whole features of EB.
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Methods: 28 mice were divided into the normal saline (NS), asthma (AS), EB, and dexamethasone (DXM) groups. The AS group received 200 μg/50 μL while the EB and DXM groups received 10 μg/50 μL OVA intranasal stimulation, while the NS group with normal saline. The DXM group received intraperitoneal injection of 5 mg/kg of DXM 1 h before stimulation. After model establishment, the cough sensitivity of the mice was evaluated. Airway reactivity with noninvasive lung function test was assessed 6h later. The percentages of eosinophils (EOS%) in the bronchoalveolar lavage fluid (BALF) and the pathological changes of the lung tissues were observed in all groups.
Results: The cough sensitivity was significantly increased in the AS, EB, and DXM groups compared to the NS group (P < 0.05). After DXM treatment, the cough sensitivity was significantly decreased compared to the AS and EB groups (P < 0.05). After stimulation with methacholine (Mch; 12.5, 25 and 50 mg/mL), the Penh was significantly higher in the AS group than in the other 3 groups (P < 0.05). No significant difference was found among the other 3 groups at any Mch concentration. The BALF and pathological results showed that the mice in the AS and EB groups had obvious airway eosinophilic inflammation and that DXM attenuated the airway inflammatory infiltration in the EB mice. an airway inflammation biomarker, but its role in clinical practice remains controversial. We therefore assessed the real-world impact of FENO in the diagnosis, treatment and 1-year outcomes of patients with suspected asthma.
Methods: Patients with suspected asthma and who had FENO done at an adult respiratory medicine clinic in 2016 were studied. Patients with pre-existing physician-diagnosed asthma were excluded. Each patient was evaluated for diagnostic and therapeutic changes and 1-year outcomes (any severe asthma exacerbation, defined as one resulting in an emergency department visit, hospitalization or death). Analyses were done using two definitions of elevated FENO: moderate (≥25 parts per billion [ppb]) or high (≥50 ppb).
Results: 171 patients (age 44.7 AE 18.0 years; 85/49.7% female; 142/83.0% never-smokers; forced vital capacity 99 AE 19% predicted; 1st-second forced expiratory volume 102 AE 20% predicted) were studied.
Median FENO was 25 ppb, interquartile range 16-48 ppb. 89 (52.1%) patients had moderate FENO elevation: they had increased asthma diagnosis (OR 10.1, 95% CI 4.1-24.8, P < 0.001), inhaled corticosteroids (OR 8.6, 95% CI 3.7-19.7, P < 0.001) and inhaled long-acting betaagonist (OR 12.7, 95% CI 3.4-48.3, P < 0.001). 41 (24.0%) patients had high FENO elevation: they had increased asthma diagnosis (OR 11.9, 95% CI 4.5-31.3, P < 0.001), inhaled corticosteroids (OR 9.3, 95% CI 3.7-23.5, P < 0.001) and inhaled long-acting beta-agonist (OR 7.8, 95% CI 3.1-19.5, P < 0.001). No patient had any severe asthma exacerbation at 1-year of follow-up.
Conclusion:
Among patients suspected to have asthma, FENO elevation was associated with increased asthma diagnosis, inhaled corticosteroid use and long-acting beta-agonist use. Background and Aims: Asthma is mediated by type 2 CD4+ Thelper cell (TH2) cytokines such as IL-4 and neutrophilic inflammation represents a distinct form of severe asthma. Rhinovirus infection promotes the release of interleukin (IL)-8, a potent chemokine recruiting neutrophils, from bronchial epithelium, and aggravates the symptoms of asthmatic patients. Nuclear factor-kB repressing factor (NKRF) reduces the basal expression of IL-8. We hypothesised that the NKRF-negative regulatory mechanism is defective in asthmatic bronchial epithelium cells, resulting in exaggerated IL-8 production upon rhinoviral infection.
Methods: Primary bronchial epithelial cells were obtained from patients with non-severe or severe asthma and non-asthmatic subjects by bronchoscopic brushing. The effect of IL-4 on the expression of NKRF, and the effect of synthetic double-strain RNA polyinosinic:polycytidylic acid (poly I:C), which activates toll-like receptor 3 resembling rhinovirus infection, on IL-8 production were evaluated by immortablised human bronchial epithelial BEAS2B cell line model. mRNA of IL-8 and NKRF in primary bronchial epithelial cells and BEAS2B cells was determined by RT-qPCR. The effect of IL-4 on NRF protein production was determined by western blotting.
Results: Primary epithelium cells from severe asthma patients expressed less NKRF mRNA and more IL-8 mRNA compared to those from non-severe asthma patients and non-asthmatic subjects. IL-4 increased NKRF in BEAS2B cells at protein level. Poly I:C attenuated the expression of NKRF mRNA but increased the expression of IL-8 in BEAS2B cells.
Bronchial epithelial cells from severe asthma patients exhibited reduced NKRF, which may be down-regulated by TH2 cytokines and further suppressed during respiratory virus infection, leading to uncontrolled IL-8 production and subsequent neutrophilic inflammation during asthmatic exacerbation.
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